- About Us
- About MS
- Teen Adventure Camp
- Contact Us
Investigators worldwide are recruiting people with relapsing-remitting MS* for a study of intravenous ocrelizumab (Genentech, Inc., and F. Hoffman La-Roche, Ltd.). This experimental drug is being evaluated in two doses, and in comparison with both a drug currently approved for the treatment of RRMS calledAvonex®(interferon beta-1a, Biogen Idec) and an inactive drug (placebo). The study is funded by Genentech, inc., F. Hoffman La-Roche, Ltd, and Biogen Idec.
The experimental drug, ocrelizumab, acts by targeting a part of the immune system (B-cells). Increasing evidence suggests that B-cells may play a role in the immune attack in MS.
People age 18 to 55 who are diagnosed with relapsing-remitting MS are eligible to participate in this study. Participants will be assigned by chance to receive one of four treatment regimens over a period of two years, which will involve either repeated intravenous infusions (ocrelizumab 2 different doses or placebo) or intramuscular injections (Avonex®). Participants who are assigned to receive placebo will switch to ocrelizumab after 24 weeks. Participants who are assigned to receive Avonex® will have the option to switch to ocrelizumab after 24 weeks.
The main objective of this study is to determine whether ocrelizumab is effective in reducing MS disease activity as observed on magnetic resonance imaging scans (MRI).
Contact: For more information on sites currently recruiting participants, please see theOcrelizumab listingin our trials participation database.
Avonex is a registered trademark of Biogen Idec.
Stony Brook University Hospital
101 Nicolls Road Stony Brook, NY 11794